Introduction
The primary cause of treatment failures in AML is the emergence of multidrug resistance. [1] [2] [3] Common mechanisms of resistant disease are defects in apoptotic pathways. Apoptosis is ultimately executed by caspases that operate both through the receptor-mediated pathway containing members of the tumor necrosis factor (TNF) family of death receptors 4, 5 and the mitochondrial-mediated pathway involving cytochrome c release from the mitochondria. 6, 7 Defects in the receptor-or mitochondrial-mediated pathway may give important prognostic information in AML, allowing risk stratification of the patients (pts). The mitochondrial-mediated pathway of apoptosis is regulated by the bcl-2 family of antiapoptotic (bcl-2, bcl-x l , mcl-1) and proapoptotic proteins (bax, bad and bak), and bcl-2 inhibits apoptosis by interacting and forming inactivating heterodimers with bax/bak. 8 Recently, bcl-2 overexpression has been associated with drug resistance in hematologic malignancies, 9 ,10 whereas a high bax level was found to be a good prognostic indicator in AML.
11
It has been suggested that the bax/bcl-2 ratio may be more important than either promoter alone in determining apoptosis. 12 However, conventional techniques, such as immunocytochemistry and Western Blot, cannot provide reliable quantitative information and are inadequate for calculating the bax/bcl-2 ratio. 11 Flow cytometry may be particularly well suited both for the precise, semiquantitative measurement of bcl-2 and bax oncoprotein expression and for the estimation of cellular heterogeneity that are frequently found in AML. 9, 11 Infact, the binding of the anti-bcl-2 or bax monoclonal antibody (MoAb) to leukemic cells is variable, which makes it difficult to define two groups, one positive and one negative. On the basis of these observations, we investigated the presence of bcl-2 and bax proteins within a large series of 255 newly diagnosed AML cases, using the mean fluorescence intensities rather than the percentages. Therefore, in our study, the use of a more sensitive, quantitative flow cytometric method allowed us to assess the strong and independent clinical significance of bax/bcl-2 ratio.
only.
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Materials and Methods
Diagnosis of AML was made on bone marrow (BM) and peripheral blood (PB) smears routinely stained and evaluated according to the revised FAB criteria. 13 The diagnosis of AML M0 was made following the guidelines proposed by the same group. 14 Immunophenotyping -Double color immunofluorescence analysis of surface antigens was performed using combinations of phycoerythrin (PE) and fluorescein isothyocyanate (FITC) conjugate MoAbs, as previously described. 15 Results were obtained by gating the appropriate "blast gate" using side scatter (SSC) versus forward light scatter (FSC) and examining the associated CD34 and CD117 expressions were also evaluated in 221 pts as mean fluorescence intensities (MFI), calculated as the ratio of CD34 or CD117 MoAb mean/negative control mean. Both CD34
percentages and MFI values were determined on the blast cells identified using FSC/SSC gating.
Intracytoplasmic and nuclear stains on cytospin preparations included: terminal deoxynucleotidyl transferase, cytoplasmic CD3 (cCD3), CD22 (cCD22) and CD13 (cCD13), myeloperoxidase only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From (MPO), as previously described. 15 Immunofluorescence was evaluated by optical examination using a Zeiss microscope equipped with an epifluorescence set, a barrier filter set for blue fluorescence, and a 100X phase contrast objective (Zeiss, Göttingen, Germany).
Cytogenetic analysis -Karyotype analysis was performed on aspirated BM cells using standard Gbanding techniques to stain metaphase preparations obtained from unstimulated cultures, as previously described. 16 Chromosome abnormalities were analysed separately and according to prognostic groups, using a modification of the Chicago classification in which a normal karyotype, of two or more groups, the log rank test was applied. The variables for which univariate analysis had shown a significant association were studied in multivariate analysis. A logistic regression model was used to assess the independent effect of covariables, treated as dichotomous, on the CR, while Cox proportional hazards regression model was employed to evaluate OS and DFS. 
Results
Patients -Approval for this study was obtained from the institutional review board. Informed consent was provided according to the Declaration of Helsinki. Criteria for inclusion in this study were: (1) diagnosis of AML other than acute promyelocytic leukemia (APL), because pts with APL were entered into a different protocol; and (2) eligibility for intensive chemotherapy. We studied 255 newly diagnosed AML cases, admitted at our unit, between 1995 and 2001, as shown in Table   1 . The pts had a median age of 63 years (range 18-80) with a performance status 2 (WHO grading system). The population studied included 116 pts aged lower than 60 and 139 pts higher than 60.
The first group was treated according to the EORTC/GIMEMA AML-10 and AML-12 randomized trials, based, as induction scheme, on the triple association of cytarabine, etoposide and an anthracycline (daunorubicin or idarubicin or mitoxantrone). Pts with an HLA-compatible sibling were allografted whenever eligible, whereas the others were randomly assigned to receive peripheral or BM stem cell transplantation. 20, 21 Pts older than 60 were entered into the EORTC/GIMEMA AML-13 randomized trial. These pts received mitoxantrone, etoposide and cytarabine as induction therapy. On achievement of CR, pts were randomly assigned to receive either an intravenous (idarubicin, etoposide and cytarabine) or an oral (idarubicin, etoposide and subcutaneously administered cytarabine) consolidation program. Fifty-one pts were transplanted (40 pts with an autologous transplant and 11 pts with an allogeneic transplant) and censored at the time of BM or PBSC infusion. 
Characteristics of bax/bcl-2 ratio in AML -
The CD34+ small percentages (1%-5%) of immature progenitors in fifty BM specimens from normal donors were used as a control group for bax/bcl-2 index: in all cases, bax/bcl-2 ratio values, No relevant association was found between bax/bcl-2 ratio and age (Table 3) . Lower than 0.3 bax/bcl-2 index was significantly associated both with the immature FAB M0-M1 subtypes (P=0.00001, Table 4 ), higher than 100 x 10 9 /L WBC count (P=0.01, Table 4 ) and CD34 >20% (P<0.00001, Table 4 ). Moreover, lower bax/bcl-2 ratio levels were significantly related to poor risk cytogenetics (P=0.0002, Table 3 ). There were also highly significant inverse correlations between bax/bcl-2 ratio values and CD34 MFI (r=-.40, P<0.000001) or CD117 MFI (r=-.29, P=0.000002),
confirming that this index is consistent with a stem-cell like feature in AML.
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Prognostic value of bax/bcl-2 index -A significant higher complete remission (CR) rate was found in pts with higher bax/bcl-2 (79% vs 45%; P=0.00001, Table 1 ). Also, both a longer overall survival (OS) and disease free survival (DFS) were observed in pts with higher bax/bcl-2 index (18% (CI, 10-38) vs 0% at 4 years; P=0.00001 and 26% (CI, only.
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On the other hand, there was no significant difference between CD34 positive (>20%) and CD34 negative (<20%) pts with regard to CR (P=0.06), OS (P=0.4) and DFS (P=0.8). However, lower bax/bcl-2 ratio was capable to identify clearly pts at poorer prognosis within the CD34 positive subgroup (n=150 pts; 42% vs 81%, P=0.00003 for CR; 3% vs 21% at 3 years, P=0.00001 for OS, Figure 3A and 0% vs 26% at 3 years, P=0.04 for DFS, Figure 3B ). only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From Interestingly, lower bax/bcl-2 ratio retained its adverse prognostic significance both within int/fav cytogenetics subgroup (n=94 pts; 70% vs 94%, P=0.002 for CR and 0% vs 26% at 2 years, P=0.02 for OS, Figure 4A ) and poor cytogenetics class (n=93 pts; 11% vs 23% at 1 year, P=0.01 for OS, Figure 4B and 21% vs 70% at 6 months, P=0.004 for DFS, Figure 4C ). The significant difference between less than 0.3 and more than 0.3 bax/bcl-2 ratio was maintained within the int/fav cytogenetics class with regard to overall survival (P=0.02). Within the poor risk cytogenetics category, pts with lower bax/bcl-2 ratio levels showed a less favorable outcome than those with higher bax/bcl-2 levels with regard to OS (B) (P=0.01) and DFS ( C ) (P=0.004).
Furthermore, lower bax/bcl-2 was closely associated with a shorter time to relapse (4±3.6 months vs 7±6.3 months; P=0.03, Figure 5A ). Noteworthy, bax/bcl-2 levels accurately predicted the clinical response and outcome of pts with normal (79/255) or unknown cytogenetics (68/255). Indeed, only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From within this subset of 147 pts, higher bax/bcl-2 was significantly associated both with a higher CR rate (86% vs 42%; P<0.00001) and a longer OS (21% vs 0% at 4 years; P=0.0016, Figure 5B ). In a logistic multivariate regression analysis of CR, bax/bcl-2 was confirmed in being a significant independent prognostic factor (odds ratio, 3.3; CI,1.3-8.4; P=0.013). Finally, using a multivariate Cox regression analysis both of OS and DFS, bax/bcl-2 mortality hazard ratios were 8.7 for OS (P=0.003) and 5.5 for DFS (P=0.019), respectively ( 
Discussion

Lower bax/bcl-2 ratio is consistent with immaturity and a worse cytogenetic pattern in AML
The biologic basis of drug resistance and relapse in AML are not well understood and prognoses are still largely based on descriptive parameters. Several lines of evidence indicate that apoptosis plays a role in response to chemotherapy, suggesting an association between therapy-induced apoptosis and therapeutic efficacy in AML. 22 Increasing evidence suggests that specific genetic alterations may abrogate apoptotic responses in myeloid tumorigenesis. High bcl-2 or low bax protein expression may contribute to leukemogenesis and drug resistance. 9, 23 The mechanisms linking these molecules to drug resistance have been experimentally addressed in AML by Banker et al. 24 In this study, most AML samples showed less treatment-associated apoptosis, suggesting that apoptotic responses to the therapeutic agents may be attenuated. All AML samples with the highest bcl-2 positive fractions showed low apoptosis. Moreover, the relative expression of pro-and antiapoptotic proteins 25 have been shown to provide an indication of chemosensitivity in solid tumors. 26 We hypothesized that bcl-2 measured in conjunction with bax would provide valuable information on the intrinsic chemosensitivity of AML, as reflected by the clinical response to treatment. Besides, among the polypeptides that are structurally and functionally related to bcl-2,
Mcl-1 has been identified. The Mcl-1 gene encodes a 36-kD polypeptide with a carboxyl terminal domain that is 35% identical to bcl-2. 27 Overexpression studies have revealed that Mcl-1 delays apoptosis induced by etoposide in myeloid leukemia cells 28 and exibits high levels at the time of leukemic relapse in AML. 29 The antiapoptotic effects of bcl-2 and Mcl-1 are opposed by a number of proapoptotic bcl-2 family members, such as bax and bak. As it is well known, bcl-2 and Mcl-1 have the ability to form heterodimers with Bax, a 22-kD polypeptide, neutralizing its effect. This results in a diminished ability of the cell to undergo apoptosis. 25 It has been demonstrated that, in CLL cells, the conformational changes of bax and bak are among the early steps in the induction of cell death. 30 Besides, after DMSO treatment, HL-60 cells died via apoptosis and the levels of the only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From apoptosis effector proteins bak and bad were enhanced, whereas there was a slight down-regulation of the apoptosis suppressor protein bcl-2. 31 Moreover, in myelodysplastic syndromes, a higher expression of pro-apoptotic proteins, such as bak, bad and bcl-x s , was associated with a longer survival and a decreased risk of leukemic transformation. 32 Our present study performed in a large series of patients identifies a distinct AML subset (130 pts), expressing lower than 0.3 bax/bcl-2 ratio, characterized by immaturity (higher CD34 and CD117 levels) and by a poor karyotype. The use of a quantitative flow cytometric method based both on bcl-2 and bax mean fluorescence intensities and their ratio allowed us to precisely define its biological and clinical potentiality.
Infact, the quantitation of fluorescence intensity seems technically adequate and useful for a more correct evaluation of clinical and prognostic correlations, as previously demonstrated. 33 Moreover, Ong et al. 11 observed that immunocytochemical techniques were both inadequate for calculating the bax/bcl-2 ratio and unable to find any significant correlation between this ratio and outcome parameters. All our AML cases were found to be bcl-2 positive, probably due to a more sensitive technical approach by direct immunofluorescence, as observed also by other Authors 10 .
Concerning the FAB classification, our data demonstrated significantly higher bax/bcl-2 ratio values in monocytic AMLs (M4 and M5), due to a lower bcl-2 MFI. This is in contrast to the report of Campos et al 9 who found a significantly higher percentage of bcl-2 positive cells in these FAB subtypes. However, our results confirm other recent observations of higher bcl-2 expression in more immature cells 34 and in immature AMLs. 10, 35 The prognostic value of bax/bcl-2 ratio may be also due to a correlation of bcl-2 with maturation. Infact, this ratio was found to be low in our CD34+
AML cases (P<0.00001), as observed by others. 35, 36 Besides, CD34 MFI values were significantly correlated with bax/bcl-2 ratio (r=-.40, P<0.000001). Moreover, a significant correlation was found between higher bcl-2 expression (MFI >14) and coexpression of the CD34 antigen, further
suggesting that the higher bcl-2 expression is more evident in less differentiated AMLs. 10 These findings could contribute to the prognostic relevance of bax/bcl-2 ratio, since CD34+ AMLs are considered to have an unfavorable outcome. 35, 37 On the contrary, in spite of the strict correlation only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From between CD34 expression and bax/bcl-2 ratio, in our experience CD34 alone did not show any clinical significance with regard to CR, OS and DFS in univariate analysis. In addition, the strong inverse correlation between bax/bcl-2 ratio and MFI CD117 values (P=0.000002) in our cases confirms the link between this index and maturation pathways, since CD117 is expressed by myeloid precursor cells 38 and its activation prevents apoptosis. 39 Besides, lower bax/bcl-2 ratio was able to identify clearly pts at unfavorable prognosis within the CD34 positive subset (Figure 3 ), demonstrating that its strong independent prognostic value is bound not only to immaturity, but probably also to a disregulation of the apoptotic pathways. Furthermore, bax/bcl-2 ratio was found to be expressed at lower levels in our poor risk cytogenetics AML subset (P=0.0002), as corroborated also by other studies. 35, 40 From literature, it is well known that chromosomal translocations associated with specific subtypes of acute leukemia result in the rearrangement of a variety of transcription factor genes. These resulting hybrid genes encode chimeric or aberrantly expressed proteins that may contribute to malignant transformation via the suppression of apoptosis.
Banker et al 24 observed that some karyotypic abnormalities, such as t(15;17), del (7) and t(9;11) exhibited lower basal apoptosis in AML. On the contrary, other Authors 10, 11 showed that the bcl-2 expression (bcl-2 mRNA, bcl-2/bax ratio or bcl-2 MFI) did not correlate to prognostic groups defined by karyotype.
Clinical significance of bax/bcl-2 ratio
From a clinical point of view, higher bax/bcl-2 ratio was significantly correlated both with a higher CR rate (Table 1) , longer time to relapse ( Figure 5A ) and a longer OS and DFS (Figures 2A and   2B ). Accordingly, Campos et al 9 demonstrated that AML pts with high levels of bcl-2 expression by immunofluorescent staining had a CR rate of 29% vs an 85% CR rate in pts with low levels.
Likewise, high levels of bcl-2 translated into decreased OS. Bcl-2 remained an important predictor of survival in multivariate analysis over other known prognostic markers, including age and WBC count of more than 30. Besides, increased levels of bax expression by immunocytochemical only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From analysis correlated with improved rates of OS in a study of 56 pts with de novo AML. 11 On the contrary, a study of 165 pts with newly diagnosed AML 41 reported that levels of bax expression by immunoblotting did not correlate with response to induction chemotherapy or survival. However, in the same study, high ratios of bcl-2 to bax protein conferred a poor prognosis with decreased rates of CR and OS. Moreover, there was a significant correlation between bcl-2 to bax expression ratio and clinical response (P<0.005) in 14 AML pts examined using an immunophosphatase staining method. 12 Along these lines, it has been demonstrated that the ratio of bcl-2 to bax correlates inversely with the sensitivity of B-chronic lymphocytic leukaemia (B-CLL) cells to cytotoxic drugs in vitro. 42 Therefore, the prognostic discrimination offered by the ratio of the proteins is greater than the bcl-2 levels alone. Also in our hands, the use of a more sensitive, quantitative method, e.g. quantitative flow cytometry, allowed us to realize the clinical prognostic potential value of this ratio, as demonstrated by our clinical results. Moreover, lower bax/bcl-2 ratio retained its unfavorable prognostic value both within int/fav and poor cytogenetic classes with regard to CR, OS and DFS (Figure 4 ). In myelodysplastic syndromes and AML secondary to MDS, bax/bcl-2 ratio was inversely correlated with both the International Prognostic Scoring System (IPI) score and cytogenetics: the highest levels were observed in pts with low IPI score and/or good risk cytogenetics. 43 Andreef et al 44 reported an unexpectedly poor survival rate associated with low bcl-2 in a group of AML pts with unfavorable cytogenetics. These preliminary data were confirmed by
Kornblau et al 41 who demonstrated that AML pts with lower bcl-2/bax ratio had an inferior response rate to induction therapy (35% vs 78%, P=0.0006) and an inferior survival outcome (median survival: 11 vs 53 weeks, P=0.00002). On the contrary, we found that a low bax/bcl-2 ratio predicted a poor outcome also within the unfavorable cytogenetic class. The explanation for this discrepancy may lie in the particular karyotypic abnormalities, such as del (7), complex karyotypes and 11q23 translocations, notoriously inhibiting apoptosis 24, 45 and very frequently found in our poor risk cytogenetics subgroup. Furthermore, we found that bax/bcl-2 ratio maintained its strong prognostic significance with regard to CR (P<0.00001) and OS (P=0.0016)
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From also within AML pts with normal or unknown cytogenetics. These data suggested that cytogenetics and bax/bcl-2 ratio were independent predictors of response and survival. In multivariate analysis low bax/bcl-2 confirmed its worse significant impact on the outcomes. In conclusion, this biological ratio is feasible and reliable through flow cytometric methods 46 and is a potentially useful prognostic indicator for tailoring the intensity of treatment. Its striking prognostic impact confirms the key role of mitochondrial apoptotic proteins, such as bcl-2 and bax, both in chemosensitivity and in future strategies for overcoming multidrug resistance in AML.
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